drugset / Trial / NCT05672524
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
Timeline
- Start
- 2022-12-30
- Primary completion
- 2027-07-30
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Tucatinib | Small molecule | 300 mg | Oral |